vs
GETTY REALTY CORP（GTY）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
GETTY REALTY CORP的季度营收约是REGENXBIO Inc.的1.9倍（$57.8M vs $30.3M），GETTY REALTY CORP净利率更高（46.0% vs -221.3%，领先267.4%），REGENXBIO Inc.同比增速更快（43.0% vs 10.5%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 7.6%）
Getty Realty Corp是一家总部位于美国的上市房地产投资信托（REIT），主要持有、租赁并管理商业地产资产组合，核心资产涵盖便利店、加油站及配套零售物业，业务覆盖美国多个州，服务零售与能源领域的优质租户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GTY vs RGNX — 直观对比
营收规模更大
GTY
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出32.5%
10.5%
净利率更高
GTY
高出267.4%
-221.3%
两年增速更快
RGNX
近两年复合增速
7.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.8M | $30.3M |
| 净利润 | $26.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 66.1% | -190.0% |
| 净利率 | 46.0% | -221.3% |
| 营收同比 | 10.5% | 43.0% |
| 净利润同比 | 80.1% | -31.2% |
| 每股收益（稀释后） | $0.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTYRGNX
| Q1 26 | $57.8M | — | ||
| Q4 25 | $60.5M | $30.3M | ||
| Q3 25 | $55.6M | $29.7M | ||
| Q2 25 | $53.3M | $21.4M | ||
| Q1 25 | $52.3M | $89.0M | ||
| Q4 24 | $53.0M | $21.2M | ||
| Q3 24 | $51.5M | $24.2M | ||
| Q2 24 | $49.9M | $22.3M |
净利润GTYRGNX
| Q1 26 | $26.6M | — | ||
| Q4 25 | $27.0M | $-67.1M | ||
| Q3 25 | $23.3M | $-61.9M | ||
| Q2 25 | $14.0M | $-70.9M | ||
| Q1 25 | $14.8M | $6.1M | ||
| Q4 24 | $22.3M | $-51.2M | ||
| Q3 24 | $15.3M | $-59.6M | ||
| Q2 24 | $16.7M | $-53.0M |
毛利率GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率GTYRGNX
| Q1 26 | 66.1% | — | ||
| Q4 25 | 67.3% | -190.0% | ||
| Q3 25 | 62.5% | -176.3% | ||
| Q2 25 | 46.7% | -296.3% | ||
| Q1 25 | 50.5% | 13.6% | ||
| Q4 24 | 61.6% | -242.1% | ||
| Q3 24 | 48.9% | -256.6% | ||
| Q2 24 | 52.5% | -251.3% |
净利率GTYRGNX
| Q1 26 | 46.0% | — | ||
| Q4 25 | 44.7% | -221.3% | ||
| Q3 25 | 42.0% | -208.3% | ||
| Q2 25 | 26.3% | -331.8% | ||
| Q1 25 | 28.3% | 6.8% | ||
| Q4 24 | 42.1% | -241.3% | ||
| Q3 24 | 29.8% | -246.3% | ||
| Q2 24 | 33.5% | -237.7% |
每股收益（稀释后）GTYRGNX
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.46 | $-1.30 | ||
| Q3 25 | $0.40 | $-1.20 | ||
| Q2 25 | $0.24 | $-1.38 | ||
| Q1 25 | $0.25 | $0.12 | ||
| Q4 24 | $0.38 | $-0.99 | ||
| Q3 24 | $0.27 | $-1.17 | ||
| Q2 24 | $0.30 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.7M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $102.7M |
| 总资产 | $2.2B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GTYRGNX
| Q1 26 | $3.7M | — | ||
| Q4 25 | $8.4M | $230.1M | ||
| Q3 25 | $5.2M | $274.2M | ||
| Q2 25 | $7.5M | $323.3M | ||
| Q1 25 | $6.3M | $267.9M | ||
| Q4 24 | $9.5M | $234.7M | ||
| Q3 24 | $4.0M | $255.5M | ||
| Q2 24 | $4.7M | $290.4M |
总债务GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | $995.0M | — | ||
| Q3 25 | $934.6M | — | ||
| Q2 25 | $919.2M | — | ||
| Q1 25 | $901.4M | — | ||
| Q4 24 | $904.3M | — | ||
| Q3 24 | $833.9M | — | ||
| Q2 24 | $838.4M | — |
股东权益GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $102.7M | ||
| Q3 25 | $1.0B | $161.5M | ||
| Q2 25 | $982.4M | $213.7M | ||
| Q1 25 | $961.1M | $274.2M | ||
| Q4 24 | $962.1M | $259.7M | ||
| Q3 24 | $963.4M | $301.4M | ||
| Q2 24 | $951.0M | $348.3M |
总资产GTYRGNX
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.0B | $581.0M | ||
| Q1 25 | $2.0B | $490.9M | ||
| Q4 24 | $2.0B | $466.0M | ||
| Q3 24 | $1.9B | $519.1M | ||
| Q2 24 | $1.9B | $569.4M |
负债/权益比GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.93× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 0.94× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | $127.4M | $-52.3M | ||
| Q3 25 | $30.5M | $-56.0M | ||
| Q2 25 | $34.7M | $-49.3M | ||
| Q1 25 | $28.7M | $33.6M | ||
| Q4 24 | $130.5M | $-31.6M | ||
| Q3 24 | $34.6M | $-40.5M | ||
| Q2 24 | $29.7M | $-45.5M |
自由现金流GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | $127.0M | $-52.8M | ||
| Q3 25 | $30.4M | $-56.5M | ||
| Q2 25 | $34.6M | $-49.7M | ||
| Q1 25 | $28.6M | $32.6M | ||
| Q4 24 | $129.6M | $-32.7M | ||
| Q3 24 | $34.4M | $-40.9M | ||
| Q2 24 | $29.6M | $-46.0M |
自由现金流率GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | 209.8% | -174.0% | ||
| Q3 25 | 54.7% | -189.9% | ||
| Q2 25 | 64.9% | -232.8% | ||
| Q1 25 | 54.7% | 36.6% | ||
| Q4 24 | 244.5% | -154.2% | ||
| Q3 24 | 66.9% | -168.9% | ||
| Q2 24 | 59.2% | -206.2% |
资本支出强度GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.3% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 1.7% | 5.1% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% |
现金转化率GTYRGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.71× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 1.94× | 5.53× | ||
| Q4 24 | 5.85× | — | ||
| Q3 24 | 2.26× | — | ||
| Q2 24 | 1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTY
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
